Search International and National Patent Collections

1. (WO2013125769) ANTIBODY-DRUG CONJUGATE COMPRISING APOLIPOPROTEIN

Pub. No.:    WO/2013/125769    International Application No.:    PCT/KR2012/009464
Publication Date: Fri Aug 30 01:59:59 CEST 2013 International Filing Date: Sat Nov 10 00:59:59 CET 2012
IPC: C07K 14/775
A61K 47/42
A61K 47/48
A61K 9/10
Applicants: RESEARCH & BUSINESS FOUNDATION SUNGKYUNKWAN UNIVERSITY
성균관대학교 산학협력단
Inventors: KWEON, Dae Hyuk
권대혁
SHIN, Jae Yoon
신재윤
Title: ANTIBODY-DRUG CONJUGATE COMPRISING APOLIPOPROTEIN
Abstract:
The present invention relates to a mutant lipoprotein which can capture drugs and in which one or more amino acid residues of a hydrophilic region exposed outwardly from the lipoprotein during drug capture are substituted by cysteine. The present invention also relates to a nanostructure in which drugs are captured inside a three-dimensional structure of the mutant lipoprotein, to a method for producing the nanostructure, to an antibody-drug conjugate (ADC) in which the nanostructure and an antibody are conjugated, and to a method for producing the conjugate. The ADC of the present invention can be produced into a form in which a significantly larger number of drugs are conjugated to an antibody compared with conventional conjugates, thus achieving excellent treatment effects of drugs. Further, the ADC of the present invention may exhibit low treatment effects or low water solubility, but may exhibit excellent treatment effects when drugs are used with superior safety, thus improving treatment safety. The ADC of the present invention does not modify the chemical structures of drugs, thus preventing risks that might be caused by a drug modification. The ADC of the present invention does not cause a complex conjugation reaction, and therefore, can be widely used in the development of effective drug therapeutic agents.